Citations

Mayo Clinic

Clear

9544 citation(s) found for "Yu, James".

Life-Course Blood Pressure Trajectories and Focal Myocardial Fibrosis in Older Age in MyoFit46
Topriceanu, Constantin-Cristian , Shiwani, Hunain , Martin, Emma , Falconer, Debbie , Bennett, Jonathan B. , Stanley, Matthew A , Gonzalez-Martin, Pablo , Tamang, Mansoon , Wong, Andrew , Pierce, Iain , Davies, Rhodri H , Lambiase, Pier D , Chaturvedi, Nishi , Kellman, Peter , Hardy, Rebecca , Moon, James C , Hughes, Alun D , Captur, Gabriella

Hypertension | October 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/hypertensionaha.126.26702 | PMID 42895024 Get It

BACKGROUND: The impact of life-course blood pressure (BP) trajectories on later-life focal left ventricular (LV) fibrosis by late gadolinium enhancement (LGE) remains elusive. METHODS: MyoFit46 prospectively recruited ≈500 participants from a 1946 birth cohort for a cardiovascular magnetic resonance scan at 77 years, assessing LV LGE calculated using the 3-SD method or 5-SD method. Systolic BP (SBP) and diastolic BP were recorded at 36, 43, 53, 63, 69, and 77 years. For each participant, annual rates of BP change (steepness) and area under the BP trajectory (cumulative burden) for each age interval were calculated using mixed-effects models. Associations between life-course BPs and LGE were tested using generalized linear models, adjusted for antihypertensives, demographics, lifestyle, and comorbidities. Time-to-event associations between LGE and incident major adverse cardiovascular event (hospitalizations for coronary artery disease, stroke, heart failure, and atrial/ventricular arrhythmias; n=29) were also evaluated. RESULTS: Among 472 participants (54% male), each 10 mm Hg greater individual SBPs at 36 to 69 years were associated with 6% to 11% greater LV LGE calculated using the 3-SD method (all P ≤0.033), whereas each 10 mm Hg sustained greater SBPs on any age interval from 36 to 69 associated with 16% to 24% greater LGE calculated using the 3-SD method at 77(all P ≤0.005), independent of SBP at 77 years. Each 1 mm Hg/y steeper SBP rise during age intervals 36 to 43, 43 to 53, and 53 to 63 was associated with 6% to 12% greater LGE calculated using the 3-SD method at 77 years. LGE presence was associated with greater major adverse cardiovascular event rates (hazard ratio, 2.5 [95% CI, 1.2–5.2]). CONCLUSIONS: Higher life-course BPs, cumulative burden, and steeper increases were associated with greater older-age LV LGE, which was linked to incident major adverse cardiovascular events. BP trajectories, beyond single-point BP measurements, warrant further investigation as tools to guide BP management strategies.
The Baseline Molecular Profile of Late Relapse: Identifying Drivers of Delayed Recurrence in DLBCL
Masar, Michal , Walker, Janek S. , Vodicka, Prokop , Dropik, Abigail R , Xianyu, Zilin , Maurer, Matthew , Habermann, Thomas , Mou, Eric , Witzig, T.E. , Ansell, Stephen M , Klener, Pavel , Cerhan, James R , Trnĕný, Marek , Wang, Yucai , Novak, Anne J

Hematological Oncology | October 12, 2026 | Volume: 44 | Issue: 6 | Pages: No page available

10.1002/hon.70275 | PMID 42861738 Get It

Serial Artificial Intelligence ECG-Derived Atrial Fibrillation Probability and Recurrence Risk After Pulsed Field Ablation
Sardana, Mayank , Rodriguez-Riascos, Juan F , Vemulapalli, Hema S , Kim, James , Attia, Zachi I , Wood, Julia , Mangold, Kathryn E , Friedman, Paul A , Noseworthy, Peter A , Srivathsan, Komandoor

Circulation: Arrhythmia and Electrophysiology | October 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/circep.126.015183 | PMID 42845233 Get It

BACKGROUND: Pulsed field ablation is now widely used for atrial fibrillation (AF) ablation, but atrial tachyarrhythmia recurrence remains common and postablation risk tools are limited. We assessed whether a validated sinus‑rhythm artificial intelligence— enabled ECG AF probability score, and its early postablation change, predicts recurrence after pulsed field ablation. METHODS: We studied consecutive patients undergoing index pulsed field ablation across 3 Mayo Clinic sites (February 2024–March 2025) with ≥1 sinus‑rhythm ECG within 180 days preprocedure. Baseline artificial intelligence—enabled ECG AF score (range 0–1) was the mean across baseline ECGs. Recovery indices (RI30/60/90), defined as mean postprocedure artificial intelligence—enabled ECG score within days 1–30/60/90 minus baseline, predicted post‑blanking recurrence using corresponding 30‑, 60‑, and 90‑day blanking windows. The primary outcome was time to first documented AF/atrial flutter/atrial tachycardia episode >30 seconds, ascertained via clinic ECGs, ambulatory monitoring, and device interrogations. Cox regression adjusted for prespecified clinical and echocardiographic covariates assessed associations; Harrell C‑statistic quantified discrimination. RESULTS: Among 1052 patients (67±10 years; 33% women), median baseline score was 0.35; 320 (30%) recurred over 188 days. Higher baseline score independently predicted recurrence (hazard ratio per 0.1 increase, 1.08 [95% CI, 1.03–1.14]). Scores rose on day 0 after ablation, then declined over subsequent weeks, with persistently higher, less‑improving trajectories among patients who recurred (time×recurrence interaction P <0.001). Day 0 score was not independently associated with recurrence after adjustment. Attenuated early recovery (higher recovery index) was independently associated with recurrence, most robustly for RI-90 (hazard ratio per 0.1 increase, 1.15 [95% CI, 1.07–1.24]), and improved discrimination beyond baseline and covariates (C‑statistic, 0.63–0.67; ΔC=0.04). Findings were consistent in a historical thermal ablation cohort. CONCLUSIONS: Baseline and early postablation dynamics of a sinus‑rhythm artificial intelligence—enabled ECG AF probability score are associated with pulsed field ablation recurrence and may aid multivariable risk stratification; prospective validation is warranted.
Potential for pathogenic protein acylation in succinate dehydrogenase-deficient pheochromocytoma and paraganglioma
III, Louis James Maher

Endocrine-Related Cancer | October 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1530/erc-26-0243 | PMID 42847134 Get It

Abstract Historically, the study of cellular metabolism and the cellular proteome have largely focused on specific proteins and metabolites in certain cellular pathways. With the advent of new “omics” technologies, researchers have been able to probe disruptions and alterations in cellular homeostasis on a near proteome-wide and metabolome-wide basis. Yet the truly interconnected and interdependent nature of the cellular metabolome and proteome has only become more evident with the discovery of proteome-wide protein post-translational modifications (PTMs) such as lysine acylation by acetyl-CoA or succinyl-CoA. Such PTMs link proteome function to fluctuating concentrations of tricarboxylic acid (TCA) cycle metabolites. Tumorigenesis in TCA cycle-defective tumors that upregulate acylating agents such as succinyl-CoA and acetyl-CoA provides a relevant context for understanding the breadth of protein acylation in disease. In particular, succinate dehydrogenase (SDH)-loss chromaffin cells can be transformed to the neuroendocrine tumors pheochromocytoma and paraganglioma (PPGL), but sensitive diagnostic and effective therapeutic options for metastatic disease remain limited. Interrogating cell models of SDH-loss PPGL provides a unique opportunity to capture the effects of SDH loss on cellular metabolism and protein acylation while exploring new avenues for improved diagnostics and novel therapeutic targets in these rare diseases.
Radiofrequency Catheter Ablation of Atrial Fibrillation in Patients with Anomalous Pulmonary Venous Return: A Multicenter Case Series
Kim, James

No container title available | October 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.30.26363976 Get It

ABSTRACT Background Atrial fibrillation (AF) has been observed in adults with anomalous pulmonary venous return (APVR), but data on catheter ablation outcomes in this population remain limited to case reports and small series. Methods We retrospectively reviewed 14 adult patients with confirmed APVR who underwent catheter ablation for AF at three tertiary academic centers in the United States between July 2003 and May 2025. Baseline, procedural, electroanatomic mapping, and outcome data were collected. Freedom from atrial arrhythmia recurrence was estimated by Kaplan-Meier analysis. Results Mean age was 56 ± 13 years and 79% were male. Heart failure was present in 64%, and hypertension and coronary artery disease in 43% each. Most had partial APVR (86%), and 57% had prior surgical correction. Radiofrequency ablation was used in all patients, combined with pulsed-field ablation in one. Acute success was achieved in all patients, although areas with residual pulmonary vein or SVC electrical activity were left untreated in 3 (21%). Non-pulmonary-vein electrical activity was more common in patients with prior surgical correction than in those without (43% vs 17%). Median follow-up was 3.4 years (IQR, 2.0-9.6). Freedom from arrhythmia recurrence was 78.6% at 1 year and 53.9% at 5 years. Two patients (14%) required reablation; complications occurred in 3 (21%) without long-term sequelae. Conclusions Catheter ablation was acutely successful in all patients in this largest reported APVR cohort, despite substantial comorbidity burden and anatomic complexity. The arrhythmogenic substrate often extended beyond the anomalous vein, particularly in surgically corrected patients, supporting individualized, substrate-guided ablation in this population. CLINICAL PERSPECTIVE What Is Known Atrial fibrillation has been reported in adults with anomalous pulmonary venous return (APVR), but data on catheter ablation outcomes in this population are limited to case reports and small series. What the Study Adds In the largest reported cohort of patients with APVR undergoing catheter ablation for atrial fibrillation, pulmonary vein isolation achieved acute success in all patients despite substantial comorbidity burden and anatomic complexity. Non-pulmonary-vein sites of electrical activity were more common among patients with prior surgical correction, and postsurgical scar and epicardial venoatrial connections were also arrhythmogenic, indicating that the arrhythmogenic substrate in APVR often extends beyond the anomalous vein itself. These findings support individualized, substrate-guided mapping in patients with APVR, particularly those with a surgical history, and suggest a role for pulsed-field ablation near critical structures such as the phrenic nerve.
‘We're All in It Together’: Emergency Nurses' Experiences of Secondary Traumatic Stress Within the Practice Environment
Camarda, Alison , Wesp, Linda , Topitzes, James , Wolf, Lisa , McAndrew, Natalie S.

Journal of Advanced Nursing | September 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/jan.70767 | PMID 42814023 Get It

ABSTRACT Aims This study aimed to describe how emergency nurses (ENs) experience secondary traumatic stress (STS) within their practice environments, focusing on the strategies they use to cope and the supportive resources they draw upon to manage its impact on their lives. Design This paper presents the qualitative findings from a larger mixed‐methods survey study on STS among ENs. Methods A geographically diverse U.S. sample of ENs was recruited through social media to participate in an online survey. All participants ( n = 275) were asked to respond to open‐ended survey questions, and 118 of these participants provided answers to at least one open‐ended question. A self‐selected sample of 20 ENs completed semi‐structured interviews. Inductive content analysis was used to analyse open‐ended survey responses and interview transcripts. Results Three themes reflected ENs' experiences with STS: STS Is Real—It's Going to Affect Your Life; Something Must Be Wrong With Me: A Culture of Disconnection; and It's a Systems Issue, but We're in It Together. Participants described individual, unit, and organizational factors that influenced their experiences of STS and their access to and use of coping strategies and supportive resources. Conclusion ENs and nurse leaders acknowledged the impact of STS on their personal and professional lives and emphasized how the practice environment shaped their experiences. They perceived the accessibility of organizational resources, leadership behaviours, and team culture as influencing the individual strategies ENs use to manage the effects of repeated exposure to others' traumatic experiences. STS is a predictable occupational hazard for ENs; thus, healthcare organizations must invest in nurse‐identified supports to preserve workforce well‐being and clinical expertise. Implications for the Profession Assessing organizational readiness to address STS is recommended to ensure ENs receive effective, timely support. In response to these assessments, healthcare organizations should develop and implement policies that prioritize the mental health and well‐being of ENs, including proactive support systems and accessible mental health resources. Impact This study identifies participant‐perceived individual, team, leadership, and organizational conditions that may hinder or support ENs' management of STS. These findings identify potential targets for organizational assessment and support strategies intended to foster healthier practice environments and promote safe, high‐quality care. Reporting Method Consolidated Criteria for Reporting Qualitative Research (COREQ). Patient or Public Contribution This study did not include patient or public involvement in its design, conduct, or reporting.
Autologous haematopoietic stem cell transplant consolidation and survival outcomes in primary central nervous system lymphoma: Evidence from the National Cancer Database
Falade, Ayo S , Ogbue, Olisaemeka D, Adeoye, Oluwatayo , Durani, Urshila , Abeykoon, Jithma P , Rosenthal, Allison C, Hilal, Talal , Iqbal, Madiha , Moustafa, Muhamad Alhaj , Chavez, Julio C , Cerhan, James R , Wang, Yucai , Zhou, Jihao

British Journal of Haematology | September 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/bjh.70861 | PMID 42812008 Get It

Predicting Oral Cancer From Precursor Lesions: The Case for a Standardized Framework of Analysis to Improve Prediction Modeling
Troka, Michael E. , Gates, James C.

Head & Neck | September 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/hed.70465 | PMID 42786126 Get It

ABSTRACT Oral Cancer often occurs from the transformation of precursor lesions, and this offers an opportunity for early detection. Current methods to assess risk of precursor lesion progression to oral cancer incompletely predict risk. A multimodal framework that leverages machine learning is needed to improve prediction. In this manuscript, we propose more standardization in the study of OPMD across sites and propose a framework aligned to the principles of the NCI's Human Tissue Atlas Network (HTAN). We explore whole exome sequencing for genomic risk, methylation array for environmental genetic regulation, RNA sequencing for transcriptional control of cellular programs with spatial transcriptomics to fulfill the spatial requirements of HTAN. Moreover, we propose a machine learning (ML) analysis whereby a learned image‐molecular association is created by integrating H&E histology and sequencing results. Once these associations are learned, a “Teacher‐Student” model can be created whereby the Student model can be deployed to infer the “molecular associations” from H&E and patient covariates alone. Such a framework integrating multiomic data across multiple different biologic processes and time points can help to better understand and potentially even predict the biologic events that underlie oral cancer initiation.
LOOP-TAG: massively-parallel measurement of length-dependent protein-mediated DNA looping probabilities by tagmentation in vitro
Kennel, Naomi R., Becker, Nicole A. , Peters, Justin P. , III, Louis James Maher

No container title available | September 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.09.21.753159 Get It

Abstract We are interested in DNA stiffness in vitro and in vivo . Classical approaches for measuring this parameter in vitro involve tedious T4 DNA ligase-mediated cyclization kinetics experiments performed for one DNA fragment length at a time to establish effective local end-end concentrations ( J -factors). Protein-mediated DNA looping is a more relevant biological reaction. An efficient approach to determine length-dependent protein-mediated DNA J - loop values in vitro has been lacking. We describe LOOP-TAG, a massively-parallel method. We leverage intramolecular DNA looping and tagmentation catalyzed by Tn5 transposase (Tnp) tethered to the terminus of a ∼1,000-bp bead-bound duplex DNA. We detected loops terminating with Tnp. Counts of the resulting DNA looping-dependent bead-bound tagmentation products from deep sequencing determine DNA loop length probabilities at single-base pair resolution for all bead-bound fragments. When normalized to DNA fragment length probabilities from tagmentation using known concentrations of free Tnp, length-dependent J - loop values are directly determined. We demonstrate LOOP-TAG for Tnp tethered in two ways and in the presence of DNA-kinking architectural DNA binding protein Nhp6A. Intermediate length J-loop values are consistent with expectations of wormlike chain theory after accounting for strong sequence-dependence of Tnp. DNA loops are shifted to smaller sizes in the presence of Nhp6A, as predicted. (200/200 words)
Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients
Kumar, Sudhesh , Warraich, Momna , Fatima, Mahnoor , McCullough, Kristen , Al‐Kali, Aref , Alkhateeb, Hassan B. , Begna, Kebede H. , Mangaonkar, Abhishek A. , Saliba, Antoine N. , Litzow, Mark R. , Hogan, William J. , Shah, Meera , Patnaik, Mrinal M. , Pardanani, Animesh , Badar, Talha , Foran, James M. , Palmer, Jeanne, Yi, Cecilia Arana, Tefferi, Ayalew , Gangat, Naseema , Warraich, Momna , Hogan, William J , Shah, Mithun V , Foran, James M , McCullough, Kristen B , Saliba, Antoine N , Saliba, Antoine N , Palmer, Jeanne , Yi, Cecilia Arana

American Journal of Hematology | September 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70500 | PMID 42755126 Get It

ABSTRACT Patients with newly‐diagnosed acute myeloid leukemia (ND‐AML) derive variable survival benefit from venetoclax (Ven) plus hypomethylating agent (HMA) therapy, and the optimal Ven duration across genetic risk groups remains undefined. Among 540 ND‐AML patients receiving Ven‐HMA at Mayo Clinic, outcomes were compared across Ven 7‐ ( n = 33), 14‐ ( n = 117), 21‐ ( n = 96), and 28‐day ( n = 294) schedules during Cycle 1 and stratified by ELN 2024 and Mayo genetic risk groups. At a median follow‐up of 37.7 months, allogeneic stem cell transplant (ASCT) rates were similar across Ven duration groups (15%, 18%, 18%, and 20% for 7‐, 14‐, 21‐, and 28‐day; p = 0.86). Median transplant‐censored survival was comparable across Ven durations (13.3, 11.9, 16.8, and 13.2 months for 7, 14, 21, 28 days, respectively; p = 0.65), with outcomes driven by ELN risk (6.3, 11.5, 18.3 months for high, intermediate, low; p < 0.01) and Mayo genetic risk (6.9, 17.8 months, not reached; p < 0.01). Survival was comparable across Ven durations within ELN intermediate/low‐risk and all Mayo risk groups. Among ELN high‐risk patients, 14‐day Ven was associated with inferior transplant‐censored survival compared to 21‐ and 28‐day schedules ( p < 0.01). Notably, 30‐ and 60‐day mortality were higher with shorter Ven schedules (7‐day: 9%/18%; 14‐day: 7%/15%) versus 28‐day (2%/6%), which likely reflects treatment selection bias. In ND‐AML, no significant difference in transplant‐censored survival was observed across the 7‐, 14‐, 21‐, and 28‐day Ven schedules; prognosis was determined primarily by Mayo and ELN 2024 genetic risk rather than by Ven duration. Prospective trials are needed to establish risk‐adapted Ven dosing strategies.